SCHEMBL21247146

SCHEMBL21247146

CC1(C)CCc2sc(NC(=O)c3ccc(N4CCOCC4)cc3)c(C(=O)O)c21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ MAPT P10636 6/20 0.47
▸ NPC1 O15118 2/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ ATM Q13315 1/20 0.47
▸ TP53 P04637 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ HDAC8 Q9BY41 2/20 0.45
▸ HDAC6 Q9UBN7 2/20 0.45
▸ MEN1 O00255 4/20 0.44
▸ KMT2A Q03164 4/20 0.44
▸ RARB P10826 1/20 0.44
▸ LRRK2 Q5S007 4/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ HDAC3 O15379 1/20 0.43
▸ HDAC4 P56524 1/20 0.43
▸ HDAC1 Q13547 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21247299 0.88 TNF (0.46) LMNAALDH1A1MAPTNPC1RAB9A
SCHEMBL21247252 0.84 RAB7A (0.59) LMNAALDH1A1MAPTNPC1RAB9A
SCHEMBL21247342 0.83 GLO1 (0.44) LMNAALDH1A1MAPTNPC1RAB9A
SCHEMBL21247286 0.83 RORC (0.54) LMNAALDH1A1MAPTNPC1RAB9A
SCHEMBL21253132 0.83 RAB9A (0.58) LMNAALDH1A1MAPTNPC1RAB9A
SCHEMBL21247283 0.82 TNF (0.61) LMNAALDH1A1MAPTNPC1RAB9A
SCHEMBL21247149 0.82 CNR1 (0.43) LMNAALDH1A1MAPTNPC1RAB9A
SCHEMBL21259038 0.80 KMT2A (0.49) LMNAALDH1A1MAPTNPC1RAB9A
SCHEMBL21247261 0.78 GLO1 (0.50) LMNAALDH1A1MAPTNPC1RAB9A
SCHEMBL21247405 0.76 RAB9A (0.62) LMNAALDH1A1MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11492347-B2 Fused thiophene derivatives and their uses ENYO PHARMA (FR) 2022-11-08 — — US disclosed
EP-3749659-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO Pharma (FR) 2020-12-16 — — EP disclosed
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-19 — — US disclosed
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-19 — — US disclosed
WO-2019154950-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 — — WO disclosed
WO-2019154950-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES FTH1, SLC40A1, FECH LMNA 4703/4885ALDH1A1 2143/4885MAPT 2107/4885
US-11492347-B2 Fused thiophene derivatives and their uses FTH1, SLC40A1, FECH LMNA 4703/4885ALDH1A1 2143/4885MAPT 2107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback